• Skip to primary navigation
  • Skip to main content

New York Society of Addiction MedicineNew York Society of Addiction Medicine Logo

  • NYSAM on Twitter
  • NYSAM on Facebook
  • NYSAM on LinkedIn
  • Join Mailing List
  • Past Conferences
  • NYSAM News
  • About
    • About NYSAM
    • Leadership
    • About Addiction Medicine
    • Contact NYSAM
    • News
  • Events
    • 2025 Annual Conference Exhibitors and Sponsors
  • Key Issues
    • Advocacy
    • Opioids
    • Marijuana
    • Access to Care
    • More Issues
  • Resources
    • For Patients
    • For Physicians
    • Webinars
    • Articles
    • Employment
  • Membership
    • NYSAM Committees
    • Become a NYSAM Member
    • Renew Membership
    • Our Members
  • Conferences
  • Latest News
  • Donate
  • Sign Up for Our Newsletter

Home » Articles » News

FDA Approves Over-the-Counter Naloxone

March 30, 2023 by NYSAM

On March 29th, the the U.S. Food and Drug Administration (FDA) approved the first nonprescription, “over-the-counter” (OTC) naloxone nasal spray, Narcan. This critical action paves the way for this life-saving medication to become available directly to consumers without a prescription. Please find more information from the HHS Press Office here, also included below.

The Biden-Harris Administration Takes Critical Action to Make Naloxone More Accessible and Prevent Fatal Overdoses from Opioids Like Fentanyl

Today, the U.S. Food and Drug Administration (FDA) approved the first nonprescription, “over-the-counter” (OTC) naloxone nasal spray, Narcan. Naloxone – a medicine that can reverse an opioid-related overdose – has been shown to be a critical tool to prevent fatal overdoses, connect more people to treatment for substance use disorder, and save lives. This action by the Biden-Harris administration to make this naloxone product available without a prescription will pave the way for the life-saving medication to be sold directly to consumers in places like drug stores, convenience stores, grocery stores and gas stations, as well as online.

“We can prevent overdoses and save lives by making naloxone more accessible, and at the same time, we can ensure equitable access to essential health care,” HHS Secretary Xavier Becerra said. “Today’s FDA action to allow access to naloxone without a prescription is another strong step forward in advancing HHS’s Overdose Prevention Strategy.”

HHS’s Overdose Prevention Strategy expands the scope of the crisis response and promotes groundbreaking research and evidence-informed methods to improve the health and safety of our communities. The Overdose Prevention Strategy helps advance the Biden-Harris Administration’s National Drug Control Strategy, which delivers on the call to action in President Biden’s Unity Agenda for a whole-of-government approach to beat the overdose epidemic.

Over the past year, the Biden-Harris Administration took unprecedented steps to expand access to naloxone and other harm reduction interventions, such as permitting the use of federal funding for state and local public health departments to purchase naloxone, focusing on state development of naloxone saturation plans, issuing guidance aimed at making it easier for harm reduction programs to obtain and distribute naloxone to at-risk populations, and prioritizing the review of nonprescription naloxone applications as appropriate. As a result of these actions, the latest CDC overdose data show a steady decrease or flattening of overdose reports for seven months in a row. To build on this progress, the Administration is focused on expanding access to naloxone, connecting more people with addiction to treatment, supporting people in recovery, and reducing the supply of illicit drugs like fentanyl.

With FDA approval of nonprescription Narcan, 4 milligram (mg) naloxone hydrochloride nasal spray, HHS will launch a department-wide approach to work with stakeholders to implement the Narcan switch from prescription to nonprescription status, facilitate the continued availability of naloxone nasal spray products during the time needed to implement the transition, and help ensure appropriate coverage and continued access to all forms of naloxone.

In addition to being used by healthcare professionals, naloxone is increasingly being distributed to first responders, and family members who may witness and respond to an opioid overdose. The availability of nonprescription and prescription naloxone could help to further increase its distribution and accessibility, potentially saving more lives and reducing the burden of opioid overdose on individuals, families, and communities.

Topics: General, Harm reduction, News, Opioids

Previous
Next
NYSAM

About NYSAM

The New York Society of Addiction Medicine is a physician-led professional community committed to the advancement of evidence-based addiction science and care. Together, we can overcome substance use disorders and the disease of addiction.View All Posts by NYSAM

Connect with Us

  • NYSAM on Twitter
  • NYSAM on Facebook
  • NYSAM on LinkedIn

Join our mailing list to stay updated on upcoming events and chapter news.

  • This field is for validation purposes and should be left unchanged.

NYSAM is a State Chapter of the American Society of Addiction Medicine (ASAM)

  • Become a Member
  • About Addiction Medicine
  • Addiction Resources
  • Physician Resources
  • Key Issues
NYSAM logo in footer

1 Capitol Mall Ste 800
Sacramento, CA 95814

For inquiries, contact Kim Andosca, Executive Director
209-499-9045
nysam@amgroup.us

© 2025 New York Society of Addiction Medicine. Website by Status Forward.